|
|
|
|
| LEADER |
03561nmm a2200301 u 4500 |
| 001 |
EB001854686 |
| 003 |
EBX01000000000000001018988 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
181201 ||| eng |
| 020 |
|
|
|a 9783319981437
|
| 100 |
1 |
|
|a Willis, Monte S.
|e [editor]
|
| 245 |
0 |
0 |
|a Fibrosis in Disease
|h Elektronische Ressource
|b An Organ-Based Guide to Disease Pathophysiology and Therapeutic Considerations
|c edited by Monte S. Willis, Cecelia C. Yates, Jonathan C. Schisler
|
| 250 |
|
|
|a 1st ed. 2019
|
| 260 |
|
|
|a Cham
|b Humana
|c 2019, 2019
|
| 300 |
|
|
|a XIX, 471 p. 62 illus., 59 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Introduction -- The Role of Chemokines in Fibrotic dermal remodeling and wound healing -- Fibrosis and immune dysregulation in systemic sclerosis -- Macrophage Plasticity in Skin Fibrosis -- Fibrotic Signaling in the Lung -- Pulmonary Matrikines: Origin, Function and Contribution to Fibrotic and Non-Fibrotic Lung Disease -- The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis -- PERICYTES AND T CELLS IN LUNG INJURY AND FIBROPROLIFERATION -- Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis -- Dynamic reciprocity- the role of the extracellular matrix microenvironment in amplifying and sustaining pathological lung fibrosis -- Fibrotic Signaling in Cardiomyopathies -- WNT SIGNALING AND CARDIAC FIBROSIS -- Matrix metalloproteinase-9-dependent mechanisms of reduced contractility and increased stiffness in the aging heart -- Using peptidomics to identify extracellular matrix-derived peptides as novel therapeutics for cardiac disease -- Vascular Fibrosis and Disease -- Liver Fibrosis: Current Approaches and Future Directions for Diagnosis and Treatment -- Tipping the balance from angiogenesis to fibrosis in chronic kidney disease -- Fibrotic Remodeling in Exudative (Wet) Macular Degeneration
|
| 653 |
|
|
|a Cardiology
|
| 653 |
|
|
|a Pathology
|
| 700 |
1 |
|
|a Yates, Cecelia C.
|e [editor]
|
| 700 |
1 |
|
|a Schisler, Jonathan C.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Molecular and Translational Medicine
|
| 028 |
5 |
0 |
|a 10.1007/978-3-319-98143-7
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-98143-7?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.07
|
| 520 |
|
|
|a This book serves as a state-of-the-art resource for physicians and translational medical researchers alike who are interested in the rapidly evolving field of fibroproliferative diseases. It provides new insight into the fundamental mechanisms of classic fibrotic pathophysiologic processes like myocardial infarction, idiopathic pulmonary fibrosis, chronic kidney disease, wound healing, and systemic sclerosis. It also highlights the many new areas of therapeutic investigation currently underway. Lastly, it touches upon newly emerging fields andinvestigates the role of fibrosis in macular degeneration and cancer metastasis. Chapters are written by established experts in their fields, including clinicians, cardiologists, cardiovascular surgeons, pathologists, general practitioners, and translational biomedical researchers in a wide range of disciplines. However, the material also applies to a broader audience, including medical residents, fellows, and M.D. or Ph.D. post-doctoral research fellows. While comprehensive, this book presents the material in a manner that simplifies the complex pathophysiologic mechanisms that underlie common fibroproliferative diseases while making it appealing to a broad audience
|